
Michael H Weisman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/271841/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. New England Journal of Medicine, 2000, 343, 1594-1602.	27.0	2,910
3	Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet, The, 1999, 354, 1932-1939.	13.7	2,266
4	Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis and Rheumatism, 2003, 48, 35-45.	6.7	1,612
5	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	21.4	1,298
6	Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nature Genetics, 2010, 42, 123-127.	21.4	573
7	Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis and Rheumatism, 1996, 39, 2013-2020.	6.7	410
8	The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 2645-2654.	6.7	391
9	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
10	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis and Rheumatism, 1999, 42, 1194-1203.	6.7	312
11	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clinical Therapeutics, 2003, 25, 1700-1721.	2.5	279
12	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	5.6	271
13	Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Annals of the Rheumatic Diseases, 2007, 66, 633-638.	0.9	225
14	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nature Communications, 2015, 6, 7146.	12.8	220
15	Brief Report: Airways abnormalities and rheumatoid arthritis–related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity?. Arthritis and Rheumatism, 2012, 64, 1756-1761.	6.7	213
16	Prevalence of axial spondylarthritis in the United States: Estimates from a crossâ€sectional survey. Arthritis Care and Research, 2012, 64, 905-910.	3.4	183
17	Dysfunctional proinflammatory highâ€density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2428-2437.	6.7	178
18	Sputum Autoantibodies in Patients With Established Rheumatoid Arthritis and Subjects at Risk of Future Clinically Apparent Disease. Arthritis and Rheumatism, 2013, 65, 2545-2554.	6.7	160

#	Article	IF	CITATIONS
19	The Epidemiology of Back Pain, Axial Spondyloarthritis and HLA-B27 in the United States. American Journal of the Medical Sciences, 2013, 345, 431-436.	1.1	149
20	Risk genotypes in folateâ€dependent enzymes and their association with methotrexateâ€related side effects in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 607-612.	6.7	148
21	Comparison of auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism, 1992, 35, 259-269.	6.7	139
22	Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease in Systemic Lupus Erythematosus. JACC: Cardiovascular Imaging, 2011, 4, 27-33.	5.3	138
23	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4lg) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	5.6	131
24	A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using firstâ€degree relatives of probands with RA. Arthritis and Rheumatism, 2009, 61, 1735-1742.	6.7	129
25	High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Annals of the Rheumatic Diseases, 2011, 70, 1619-1624.	0.9	128
26	Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. Arthritis and Rheumatology, 2016, 68, 312-322.	5.6	128
27	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sj¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	5.6	114
28	A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2014, 66, 130-139.	5.6	103
29	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 2372-2380.	6.7	96
30	Anti–Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2017, 69, 1165-1175.	5.6	93
31	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 1243-1249.	0.9	93
32	<i>ERAP2</i> is associated with ankylosing spondylitis in <i>HLA-B27</i> positive and <i>HLA-B27-</i> negative patients. Annals of the Rheumatic Diseases, 2015, 74, 1627-1629.	0.9	86
33	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. Arthritis and Rheumatology, 2014, 66, 2649-2656.	5.6	81
34	The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10. Annals of the Rheumatic Diseases, 2013, 72, 369-373.	0.9	79
35	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. Arthritis and Rheumatism, 1999, 42, 357-365.	6.7	78
36	Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1980, 23, 119-122.	6.7	73

#	Article	IF	CITATIONS
37	Occupational physical activities and longâ€ŧerm functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2008, 59, 822-832.	6.7	72
38	Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 147-152.	0.9	72
39	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 2162-6.	2.0	71
40	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. Clinical Immunology, 2016, 168, 25-29.	3.2	68
41	MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. Journal of Autoimmunity, 2017, 79, 105-111.	6.5	66
42	What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. Journal of rheumatology Supplement, The, 2002, 65, 33-8.	2.2	65
43	Performance of Anti–Cyclic Citrullinated Peptide Assays Differs in Subjects at Increased Risk of Rheumatoid Arthritis and Subjects With Established Disease. Arthritis and Rheumatism, 2013, 65, 2243-2252.	6.7	64
44	Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Annals of the Rheumatic Diseases, 2019, 78, 1235-1241.	0.9	64
45	Chronic Inflammatory Demyelinating Polyneuropathy in Patients with Systemic Lupus Erythematosus: Prognosis and Outcome. Seminars in Arthritis and Rheumatism, 2005, 35, 175-184.	3.4	62
46	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genetics, 2017, 13, e1006820.	3.5	60
47	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2020, 79, 193-201.	0.9	59
48	A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology, 2007, 46, 1122-1125.	1.9	57
49	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis and Rheumatology, 2017, 69, 630-642.	5.6	56
50	Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. Rheumatology, 2016, 55, 367-376.	1.9	52
51	HLA class I and II alleles in susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2019, 78, 66-73.	0.9	52
52	Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2009, 11, R182.	3.5	51
53	Antibody Responses to Citrullinated and Noncitrullinated Antigens in the Sputum of Subjects With Rheumatoid Arthritis and Subjects at Risk for Development of Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 516-527.	5.6	51
54	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 1168-1174.	0.9	49

#	Article	IF	CITATIONS
55	Quality-adjusted life years lost to arthritis: Effects of gender, race, and social class. Arthritis and Rheumatism, 1996, 9, 473-482.	6.7	48
56	Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody―blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Research and Therapy, 2015, 17, 215.	3.5	48
57	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 1552-1557.	0.9	47
58	Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected Firstâ€Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1828-1838.	5.6	46
59	Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Research and Therapy, 2012, 14, R261.	3.5	44
60	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Human Molecular Genetics, 2018, 27, 3813-3824.	2.9	43
61	Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology, 2016, 55, 1195-1201.	1.9	42
62	Combined role of vitamin D status and <i>CYP24A1</i> in the transition to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 153-158.	0.9	40
63	Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 16-26.	2.0	38
64	Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration. American Journal of Pathology, 2017, 187, 146-155.	3.8	38
65	Psychological Correlates of Self-reported Disease Activity in Ankylosing Spondylitis. Journal of Rheumatology, 2010, 37, 829-834.	2.0	36
66	Inflammatory Back Pain. Rheumatic Disease Clinics of North America, 2012, 38, 501-512.	1.9	36
67	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 2187-2192.	5.6	35
68	Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clinical Rheumatology, 2017, 36, 2359-2364.	2.2	35
69	A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	2.9	34
70	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. JCI Insight, 2018, 3, .	5.0	34
71	Reversible cause of back pain and sciatica in rheumatoid arthritis: An apophyseal joint cyst. Arthritis and Rheumatism, 1986, 29, 431-435.	6.7	31
72	Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. Clinical Rheumatology, 2017, 36, 1311-1316.	2.2	27

#	Article	IF	CITATIONS
73	The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever. BioMed Research International, 2014, 2014, 1-8.	1.9	25
74	Psychological Factors that Link Socioeconomic Status to Depression/Anxiety in Patients with Systemic Lupus Erythematosus. Journal of Clinical Psychology in Medical Settings, 2017, 24, 302-315.	1.4	25
75	Effect of Tobacco Smoking on The Clinical, Histopathological, and Serological Manifestations of Sjögren's Syndrome. PLoS ONE, 2017, 12, e0170249.	2.5	25
76	Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Largeâ€Scale Survey of Social Media Platforms. Arthritis Care and Research, 2019, 71, 323-330.	3.4	25
77	Biologics, spondylitis and COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1663-1665.	0.9	25
78	Progress toward the cure of rheumatoid arthritis? The best study. Arthritis and Rheumatism, 2005, 52, 3326-3332.	6.7	24
79	Strong viral associations with SLE among Filipinos. Lupus Science and Medicine, 2017, 4, e000214.	2.7	24
80	Development and validation of a case ascertainment tool for ankylosing spondylitis. Arthritis Care and Research, 2010, 62, 19-27.	3.4	23
81	The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?. RMD Open, 2021, 7, e001558.	3.8	23
82	Prevalence of Chronic Axial Pain, Inflammatory Back Pain, and Spondyloarthritis in Diagnosed Psoriasis. Arthritis Care and Research, 2015, 67, 829-835.	3.4	22
83	Brief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif–Containing Protein 38 Show Greater Disease Severity. Arthritis and Rheumatology, 2016, 68, 724-729.	5.6	22
84	Interstitial lung abnormalities in patients with early rheumatoid arthritis: A pilot study evaluating prevalence and progression. European Journal of Rheumatology, 2019, 6, 193-198.	0.6	22
85	Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2019, 71, 1647-1652.	3.4	21
86	Fiveâ€Year Followâ€Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Communityâ€Based Lupus Cohort. Arthritis Care and Research, 2020, 72, 882-887.	3.4	21
87	Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. Arthritis Care and Research, 2020, 72, 1645-1652.	3.4	21
88	Perceived Stress and Inflammatory Arthritis: A Prospective Investigation in the Studies of the Etiologies of Rheumatoid Arthritis Cohort. Arthritis Care and Research, 2020, 72, 1766-1771.	3.4	21
89	Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Annals of the Rheumatic Diseases, 2021, 80, 154-161.	0.9	21
90	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. Journal of Rheumatology, 2018, 45, 188-194.	2.0	20

#	Article	IF	CITATIONS
91	The Effect of HLA-B27 on Susceptibility and Severity of COVID-19. Journal of Rheumatology, 2021, 48, 621-622.	2.0	19
92	Primary lymphoma of the calcaneus. Skeletal Radiology, 1996, 25, 775-778.	2.0	18
93	Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine, 2019, 42, 76-85.	6.1	18
94	A promising approach to targeting type 1 IFN in systemic lupus erythematosus. Journal of Clinical Investigation, 2019, 129, 958-961.	8.2	18
95	Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000247.	2.7	16
96	Trends in Functional Disability and Determinants of Clinically Meaningful Change Over Time in Hispanic Patients With Rheumatoid Arthritis in the US. Arthritis Care and Research, 2017, 69, 294-298.	3.4	15
97	US National Health and Nutrition Examination Survey Arthritis Initiatives, Methodologies and Data. Rheumatic Disease Clinics of North America, 2018, 44, 215-265.	1.9	15
98	Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis. Journal of Rheumatology, 2019, 46, 1582-1588.	2.0	15
99	Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960–2014. PLoS ONE, 2020, 15, e0226516.	2.5	15
100	Relationships of Positive and Negative Affect to Coping and Functional Outcomes in Systemic Sclerosis. Cognitive Therapy and Research, 2004, 28, 593-610.	1.9	14
101	Spine fractures in ankylosing spondylitis: A case report and review of imaging as well as predisposing factors to falls and fractures. Seminars in Arthritis and Rheumatism, 2014, 44, 20-24.	3.4	14
102	Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2018, 21, 850-858.	1.9	14
103	Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. Contemporary Clinical Trials Communications, 2018, 11, 127-135.	1.1	14
104	American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans. Arthritis Care and Research, 2020, 72, 1049-1056.	3.4	14
105	A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus. ACR Open Rheumatology, 2021, 3, 209-220.	2.1	14
106	New Populationâ€Based Reference Values for Spinal Mobility Measures Based on the 2009–2010 National Health and Nutrition Examination Survey. Arthritis and Rheumatology, 2014, 66, 2628-2637.	5.6	13
107	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis and Rheumatology, 2020, 72, 1067-1071.	5.6	13
108	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Molecular Medicine, 2018, 24, 24.	4.4	12

#	Article	IF	CITATIONS
109	Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. International Journal of Molecular Sciences, 2018, 19, 2331.	4.1	12
110	Anticyclic Citrullinated Peptide Antibodies 3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 1556-1559.	2.0	12
111	Clinical features related to statinâ€associated muscle symptoms. Muscle and Nerve, 2019, 59, 537-543.	2.2	12
112	Examining Treatment Decisionâ€Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. ACR Open Rheumatology, 2020, 2, 391-400.	2.1	12
113	Current Controversies in Spondyloarthritis: SPARTAN. Journal of Rheumatology, 2010, 37, 2617-2623.	2.0	11
114	A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits. BMC Medical Research Methodology, 2018, 18, 8.	3.1	11
115	Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs. RMD Open, 2022, 8, e001777.	3.8	11
116	Microvascular Angina: An Underappreciated Cause of SLE Chest Pain. Journal of Rheumatology, 2013, 40, 746-747.	2.0	10
117	Spondyloarthritis evolution: what is in your history?. Current Opinion in Rheumatology, 2020, 32, 321-329.	4.3	10
118	Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti–Citrullinated Protein Antibody–Positive Population. Arthritis and Rheumatology, 2021, 73, 955-962.	5.6	10
119	Development of a new instrument for rheumatoid arthritis: The Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA). Arthritis and Rheumatism, 2003, 49, 78-84.	6.7	9
120	Functional Limitations Due to Axial and Peripheral Joint Impairments in Patients With Ankylosing Spondylitis: Are Focused Measures More Informative?. Arthritis Care and Research, 2013, 65, 607-614.	3.4	9
121	Causes and Predictors of Early Hospital Readmission in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 929-933.	2.0	9
122	New-onset non-infectious pulmonary manifestations among patients with systemic lupus erythematosus in Sweden. Arthritis Research and Therapy, 2019, 21, 48.	3.5	9
123	Drivers of Satisfaction With Care for Patients With Lupus. ACR Open Rheumatology, 2019, 1, 649-656.	2.1	9
124	The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. Journal of Rheumatology, 2022, 49, 225-229.	2.0	9
125	The role of methotrexate in psoriatic arthritis: what is the evidence?. Clinical and Experimental Rheumatology, 2015, 33, S94-7.	0.8	9
126	Development and validation of Cedars-Sinai Health-Related Quality of Life in Rheumatoid Arthritis (CSHQ-RA) short form instrument. Arthritis and Rheumatism, 2004, 51, 358-364.	6.7	8

#	Article	IF	CITATIONS
127	Monoclonal Antibodies, Systemic Lupus Erythematosus, and Pregnancy: Insights from an Open-label Study. Journal of Rheumatology, 2015, 42, 728-730.	2.0	8
128	Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease. Journal of Clinical Rheumatology, 2019, 25, 45-49.	0.9	8
129	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. Rheumatology International, 2020, 40, 1053-1061.	3.0	8
130	Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort. Rheumatology, 2022, 61, 2079-2087.	1.9	8
131	A Case of Henoch-Schonlein Purpura Associated with Rotavirus Infection in an Elderly Asian Male and Review of the Literature. American Journal of Case Reports, 2017, 18, 136-142.	0.8	8
132	HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. Scientific Reports, 2021, 11, 12331.	3.3	7
133	Incidence of Ankylosing Spondylitis Among Male and Female United States Army Personnel. Arthritis Care and Research, 2023, 75, 332-339.	3.4	7
134	A United States expert consensus to standardise definitions, followâ€up, and treatment targets for extraâ€intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	3.7	7
135	Hydroxychloroquine — How Much Is Too Much?. Journal of Rheumatology, 2019, 46, 340-342.	2.0	6
136	A review of non-immune mediated kidney disease in systemic lupus erythematosus: A hypothetical model of putative risk factors. Seminars in Arthritis and Rheumatism, 2020, 50, 463-472.	3.4	6
137	The road to rheumatoid arthritis prevention: challenges and opportunities. Clinical Rheumatology, 2020, 39, 1379-1381.	2.2	6
138	Insights From Twitter Conversations on Lupus and Reproductive Health: Protocol for a Content Analysis. JMIR Research Protocols, 2020, 9, e15623.	1.0	6
139	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology, 2022, 61, 4335-4343.	1.9	6
140	Lung abnormalities in subjects with elevations of rheumatoid arthritis-related autoantibodies without arthritis by examination and imaging suggest the lung is an early and perhaps initiating site of inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A25.1-A25.	0.9	5
141	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	2.7	5
142	Multidimensional Model of Disability and Role Functioning in Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 1686-1692.	3.4	4
143	Association of Antibodies to Citrullinated Protein Antigens with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis. American Journal of Nephrology, 2017, 46, 481-487.	3.1	4
144	Correspondence on â€~Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'. Annals of the Rheumatic Diseases, 2023, 82, e138-e138.	0.9	4

#	Article	IF	CITATIONS
145	Risk Factors for Spinal Structural Damage in a Chinese Cohort With Ankylosing Spondylitis. Journal of Clinical Rheumatology, 2022, 28, e118-e124.	0.9	4
146	Manure shoveler's hip: A previously unrecognized syndrome. Arthritis and Rheumatism, 1979, 22, 940-941.	6.7	3
147	Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction. Current Opinion in Rheumatology, 2016, 28, 303-309.	4.3	3
148	The changing profile of ankylosing spondylitis in the biologic era. Clinical Rheumatology, 2020, 39, 2641-2651.	2.2	3
149	Prevalence of sacroiliitis among patients referred for hip MR arthrography. Skeletal Radiology, 2021, , 1.	2.0	3
150	Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time. RMD Open, 2020, 6, e001418.	3.8	3
151	The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. Journal of Rheumatology, 2021, , jrheum.210332.	2.0	3
152	Does Gender Impact a Diagnosis of Ankylosing Spondylitis?. ACR Open Rheumatology, 2022, 4, 540-546.	2.1	3
153	Do all drugs and treatments for rheumatoid arthritis have the same efficacy?. Nature Clinical Practice Rheumatology, 2008, 4, 298-299.	3.2	2
154	Chest pain in lupus patients: the emergency department experience. Clinical Rheumatology, 2015, 34, 1969-1973.	2.2	2
155	Corticosteroids. Rheumatic Disease Clinics of North America, 2016, 42, xiii.	1.9	2
156	A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values. Journal of Biopharmaceutical Statistics, 2020, 30, 160-177.	0.8	2
157	Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach. Journal of Scleroderma and Related Disorders, 2020, 5, 231-236.	1.7	2
158	Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis. Medicine (United States), 2021, 100, e25558.	1.0	2
159	Evaluating associations of joint swelling, joint stiffness and joint pain with physical activity in first-degree relatives of patients with rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA), a prospective cohort study. BMJ Open, 2021, 11, e050883.	1.9	2
160	Spondyloarthritis: The Changing Landscape—Are We There Yet?. Rheumatic Disease Clinics of North America, 2020, 46, xiii-xiv.	1.9	2
161	Foreword. Rheumatic Disease Clinics of North America, 2014, 40, xiii.	1.9	1
162	Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2015, 41, xiii.	1.9	1

#	Article	IF	CITATIONS
163	Sjogren's Disease. Rheumatic Disease Clinics of North America, 2016, 42, xi-xii.	1.9	1
164	Patient-Reported Outcomes in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2016, 42, xiii-xiv.	1.9	1
165	Editorial: The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus Is Perhaps Not a Paradox. Arthritis and Rheumatology, 2017, 69, 1707-1709.	5.6	1
166	Relationship between the gut and the spine: a pilot study of first-degree relatives of patients with ankylosing spondylitis. RMD Open, 2017, 3, e000437.	3.8	1
167	The Brave New World of Rheumatic Disease Research Today. Rheumatic Disease Clinics of North America, 2018, 44, xiii.	1.9	1
168	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. Lupus, 2021, 30, 1790-1798.	1.6	1
169	The Need for SPACE to Plan the Future for Spondyloarthritis. Journal of Rheumatology, 2022, 49, 341-342.	2.0	1
170	Foreword. Rheumatic Disease Clinics of North America, 2012, 38, ix-x.	1.9	0
171	Foreword. Rheumatic Disease Clinics of North America, 2012, 38, xiii-xv.	1.9	0
172	Foreword. Rheumatic Disease Clinics of North America, 2013, 39, xv.	1.9	0
173	Foreword. Rheumatic Disease Clinics of North America, 2013, 39, ix.	1.9	0
174	Foreword. Rheumatic Disease Clinics of North America, 2013, 39, xiii.	1.9	0
175	Gout and Crystal Arthropathies. Rheumatic Disease Clinics of North America, 2014, 40, xiii.	1.9	0
176	Foreword. Rheumatic Disease Clinics of North America, 2014, 40, xi.	1.9	0
177	Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, xi.	1.9	Ο
178	Foreword. Rheumatic Disease Clinics of North America, 2015, 41, xi.	1.9	0
179	Imaging in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2016, 42, xiii.	1.9	0
180	Reproductive Health. Rheumatic Disease Clinics of North America, 2017, 43, xi-xii.	1.9	0

#	Article	IF	CITATIONS
181	Neurologic Manifestations of Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2017, 43, xi.	1.9	О
182	Infection and Malignancy in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2017, 43, xi-xii.	1.9	0
183	Digestive and Hepatic Aspects of the Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2018, 44, xiii-xiv.	1.9	0
184	Renal Involvement in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2018, 44, xi.	1.9	0
185	Etiology unknown: Qualitative analysis of patient attributions of causality in scleroderma. Journal of Scleroderma and Related Disorders, 2018, 3, 182-188.	1.7	Ο
186	Rheumatic Diseases in Older Adults. Rheumatic Disease Clinics of North America, 2018, 44, xi-xii.	1.9	0
187	Technology and Big Data in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xiii-xiv.	1.9	Ο
188	THU0358â€DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
189	Controversies in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xiii-xiv.	1.9	Ο
190	Treat to Target in Rheumatic Diseases: Rationale and Results. Rheumatic Disease Clinics of North America, 2019, 45, ix-x.	1.9	0
191	Best Practices and Challenges to the Practice of Rheumatologists. Rheumatic Disease Clinics of North America, 2019, 45, xiii-xiv.	1.9	Ο
192	Education and Professional Development in Rheumatology. Rheumatic Disease Clinics of North America, 2020, 46, xiii-xiv.	1.9	0
193	Foreword. Rheumatic Disease Clinics of North America, 2020, 46, xi.	1.9	Ο
194	Foreword. Rheumatic Disease Clinics of North America, 2021, 47, xi-xii.	1.9	0
195	Pulse dose steroid experience among hospitalized patients with systemic lupus erythematosus: a single-center feasibility study. Clinical Rheumatology, 2021, 40, 1317-1320.	2.2	Ο
196	Pain in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2021, 47, xi-xii.	1.9	0
197	Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis. ACR Open Rheumatology, 2021, 3, 413-421.	2.1	0
198	Lupus. Rheumatic Disease Clinics of North America, 2021, 47, xiii-xiv.	1.9	0

#	Article	IF	CITATIONS
199	Genomics in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2017, 43, xiii-xiv.	1.9	0
200	Foreword. Rheumatic Disease Clinics of North America, 2020, 46, xiii-xiv.	1.9	0
201	Chronic inflammatory back pain commencing late in life: a neglected concept. Internal Medicine Journal, 2022, 52, 485-487.	0.8	0